Are Some Cancer Drugs Costing Too Much for Too Little?

Article

Newer cancer drugs are being approved on the basis of shorter studies and on outcomes that might not predict living longer or feeling better.

Newer cancer drugs are being approved on the basis of shorter studies and on outcomes that might not predict living longer or feeling better, according to a new article published in JAMA Internal Medicine.

Investigators looked at 18 cancer drugs approved by the US Food and Drug Administration (FDA) between 2008 and 2012. All of these drugs were not shown in postmarket studies to significantly prolong overall survival (OS). 

The researchers found that the estimated annual costs of the 18 drugs ranged from $20,237 (rituximab) to $169,836 (cabozantinib-S-malate). They found that 13 drugs had annual costs that exceeded $100, 000 and the most expensive drug (cabozantinib) did not improve OS and worsened quality of life (QOL) compared with placebo.

“I was very surprised by the findings. Keep in mind, that these studies were conducted and funded by the companies whose products were being evaluated, not by outsiders. I was even more surprised when I talked to FDA officials and heard from officials from some of the companies involved. They were all very defensive, saying essentially well even though the data so far show that the drug has no benefit for overall survival or quality of life, we think that it really does have a benefit," Diana Zuckerman, PhD, who is the President at the National Center for Health Research, Washington, DC, told OncoTherapy Network.

Zuckerman and colleagues searched PubMed for clinical trial data and analyzed all peer-reviewed findings and FDA review summaries for QOL. They also calculated the annual costs for these. “They keep analyzing the data in different ways until they finally find something that looks more promising. For example, maybe a small genetic subset of patients do a little better, but the label won't be that specific, it will say the drug is approved for all patients with lung cancer, or colorectal cancer, or whatever,” said Zuckerman.

The PubMed search identified 466 articles; however, only 31 met the study inclusion criteria of a clinical trial with a comparison group using a validated QOL survey instrument. They also analyzed FDA review summaries, but publicly available summaries were only available on 15 of the 18 drugs. The QOL studies compared seven drugs with placebo or observation groups and found that two drugs demonstrated worse effects on QOL. The remaining five drugs showed no statistical difference or had mixed results.

The researchers question whether drugs that are costing this much money should retain FDA approval and remain on the market when postmarket studies show they no clinically meaningful benefit compared with placebo or observation.

“The most important message for oncologists is to check out the data on new cancer drugs for themselves whenever possible. Cancer patients care about living longer and feeling better, and that is more important than whether the tumor shrinks for a while,” Zuckerman. “We encourage oncologists to look at results for overall survival not progression-free survival.”

                                                   

 

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content